Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / NYU Lung Cancer Biomarker Center

NYU Lung Cancer Biomarker Center

24

No coordinating investigator defined.

No involved investigator sites defined.

UNKNOWN
Lung and Upper Aerodigestive Cancers Research Group

A. SPECIFIC AIMS 1. To develop and prospectively follow a large cohort at high-risk for lung cancer. Individuals are recruited to one of two different study groups: The Screening Cohort includes people with and without increased risk for lung cancer. The Rule-Out Lung Cancer Patient Group is recruited from patients referred for evaluation of suspicious nodules. All individuals answer a questionnaire, obtain PFTs, chest CT scan, sputum induction and phlebotomy. For patients undergoing lung resections or biopsies, tissue samples are collected and banked. Individuals are recruited for research bronchoscopy. All participants are then followed prospectively. The specimens obtained are banked and used for biomarker discovery and validation studies. 2. To identify and validate biomarkers for the early detection of lung cancer, and to describe preneoplastic cellular changes and lesions. Biomarker studies include DNA adducts, DNA methylation, protein markers, and other collaborations. Preneoplasia studies include: fluorescence and Superdimension bronchoscopies to obtain biopsies of preneoplastic lesions and biomarker studies in individuals with preneoplasias.

A. SPECIFIC AIMS 1. To develop and prospectively follow a large cohort at high-risk for lung cancer. Individuals are recruited to one of two different study groups: The Screening Cohort includes people with and without increased risk for lung cancer. The Rule-Out Lung Cancer Patient Group is recruited from patients referred for evaluation of suspicious nodules. All individuals answer a questionnaire, obtain PFTs, chest CT scan, sputum induction and phlebotomy. For patients undergoing lung resections or biopsies, tissue samples are collected and banked. Individuals are recruited for research bronchoscopy. All participants are then followed prospectively. The specimens obtained are banked and used for biomarker discovery and validation studies. 2. To identify and validate biomarkers for the early detection of lung cancer, and to describe preneoplastic cellular changes and lesions. Biomarker studies include DNA adducts, DNA methylation, protein markers, and other collaborations. Preneoplasia studies include: fluorescence and Superdimension bronchoscopies to obtain biopsies of preneoplastic lesions and biomarker studies in individuals with preneoplasias.

No datasets are currently associated with this protocol.


2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.